Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

881 related articles for article (PubMed ID: 16080463)

  • 1. Differential effect of anti-apoptotic genes Bcl-xL and c-FLIP on sensitivity of MCF-7 breast cancer cells to paclitaxel and docetaxel.
    Wang Z; Goulet R; Stanton KJ; Sadaria M; Nakshatri H
    Anticancer Res; 2005; 25(3c):2367-79. PubMed ID: 16080463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small inhibitor of Bcl-2, HA14-1, selectively enhanced the apoptotic effect of cisplatin by modulating Bcl-2 family members in MDA-MB-231 breast cancer cells.
    Arisan ED; Kutuk O; Tezil T; Bodur C; Telci D; Basaga H
    Breast Cancer Res Treat; 2010 Jan; 119(2):271-81. PubMed ID: 19238538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paclitaxel sensitivity of breast cancer cells requires efficient mitotic arrest and disruption of Bcl-xL/Bak interaction.
    Flores ML; Castilla C; Ávila R; Ruiz-Borrego M; Sáez C; Japón MA
    Breast Cancer Res Treat; 2012 Jun; 133(3):917-28. PubMed ID: 22076480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bcl-2 and Bcl-xL are important for the induction of paclitaxel resistance in human hepatocellular carcinoma cells.
    Chun E; Lee KY
    Biochem Biophys Res Commun; 2004 Mar; 315(3):771-9. PubMed ID: 14975768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antisense Bcl-2 and HER-2 oligonucleotide treatment of breast cancer cells enhances their sensitivity to anticancer drugs.
    Tanabe K; Kim R; Inoue H; Emi M; Uchida Y; Toge T
    Int J Oncol; 2003 Apr; 22(4):875-81. PubMed ID: 12632082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreased response to paclitaxel versus docetaxel in HER-2/neu transfected human breast cancer cells.
    Witters LM; Santala SM; Engle L; Chinchilli V; Lipton A
    Am J Clin Oncol; 2003 Feb; 26(1):50-4. PubMed ID: 12576925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanomolar range docetaxel treatment sensitizes MCF-7 cells to chemotherapy induced apoptosis, induces G2M arrest and phosphorylates bcl-2.
    Berchem GJ; Bosseler M; Mine N; Avalosse B
    Anticancer Res; 1999; 19(1A):535-40. PubMed ID: 10226594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. miRNA-34a is associated with docetaxel resistance in human breast cancer cells.
    Kastl L; Brown I; Schofield AC
    Breast Cancer Res Treat; 2012 Jan; 131(2):445-54. PubMed ID: 21399894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell death induced by taxanes in breast cancer cells: cytochrome C is released in resistant but not in sensitive cells.
    Ehrlichová M; Koc M; Truksa J; Naldová Z; Václavíková R; Kovárr J
    Anticancer Res; 2005; 25(6B):4215-24. PubMed ID: 16309219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Death receptor 4 (DR4) efficiently kills breast cancer cells irrespective of their sensitivity to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
    Kazhdan I; Marciniak RA
    Cancer Gene Ther; 2004 Oct; 11(10):691-8. PubMed ID: 15354201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The function of multiple IkappaB : NF-kappaB complexes in the resistance of cancer cells to Taxol-induced apoptosis.
    Dong QG; Sclabas GM; Fujioka S; Schmidt C; Peng B; Wu T; Tsao MS; Evans DB; Abbruzzese JL; McDonnell TJ; Chiao PJ
    Oncogene; 2002 Sep; 21(42):6510-9. PubMed ID: 12226754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. "Loop" domain is necessary for taxol-induced mobility shift and phosphorylation of Bcl-2 as well as for inhibiting taxol-induced cytosolic accumulation of cytochrome c and apoptosis.
    Fang G; Chang BS; Kim CN; Perkins C; Thompson CB; Bhalla KN
    Cancer Res; 1998 Aug; 58(15):3202-8. PubMed ID: 9699642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor suppressor BLU promotes paclitaxel antitumor activity by inducing apoptosis through the down-regulation of Bcl-2 expression in tumorigenesis.
    Park ST; Byun HJ; Kim BR; Dong SM; Park SH; Jang PR; Rho SB
    Biochem Biophys Res Commun; 2013 May; 435(1):153-9. PubMed ID: 23628417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antisense RNA down-regulation of bcl-xL Expression in prostate cancer cells leads to diminished rates of cellular proliferation and resistance to cytotoxic chemotherapeutic agents.
    Vilenchik M; Raffo AJ; Benimetskaya L; Shames D; Stein CA
    Cancer Res; 2002 Apr; 62(7):2175-83. PubMed ID: 11929841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of apoptosis in human breast cancer cells by nimbolide through extrinsic and intrinsic pathway.
    Elumalai P; Gunadharini DN; Senthilkumar K; Banudevi S; Arunkumar R; Benson CS; Sharmila G; Arunakaran J
    Toxicol Lett; 2012 Nov; 215(2):131-42. PubMed ID: 23089555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of cell death events induced by anti-neoplastic drugs cisplatin, paclitaxel and 5-fluorouracil on human hepatoma cell lines: Possible mechanisms of cell resistance.
    Brenes O; Arce F; Gätjens-Boniche O; Díaz C
    Biomed Pharmacother; 2007 Jul; 61(6):347-55. PubMed ID: 17399942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peripheral benzodiazepine receptor ligands induce apoptosis and cell cycle arrest in human hepatocellular carcinoma cells and enhance chemosensitivity to paclitaxel, docetaxel, doxorubicin and the Bcl-2 inhibitor HA14-1.
    Sutter AP; Maaser K; Grabowski P; Bradacs G; Vormbrock K; Höpfner M; Krahn A; Heine B; Stein H; Somasundaram R; Schuppan D; Zeitz M; Scherübl H
    J Hepatol; 2004 Nov; 41(5):799-807. PubMed ID: 15519653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bcl-XL is qualitatively different from and ten times more effective than Bcl-2 when expressed in a breast cancer cell line.
    Fiebig AA; Zhu W; Hollerbach C; Leber B; Andrews DW
    BMC Cancer; 2006 Aug; 6():213. PubMed ID: 16928273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of Siva-1 protein or its putative amphipathic helical region enhances cisplatin-induced apoptosis in breast cancer cells: effect of elevated levels of BCL-2.
    Chu F; Barkinge J; Hawkins S; Gudi R; Salgia R; Kanteti PV
    Cancer Res; 2005 Jun; 65(12):5301-9. PubMed ID: 15958577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ZD1839 (IRESSA), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells.
    Ciardiello F; Caputo R; Borriello G; Del Bufalo D; Biroccio A; Zupi G; Bianco AR; Tortora G
    Int J Cancer; 2002 Mar; 98(3):463-9. PubMed ID: 11920601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.